The current treatment strategy for gouty arthritis
Febuxostat is a non-purine selective inhibitor of isoforms of xanthine oxidoreductase (XOR), the effect of which is aimed at lowering the level of serum uric acid (UA). Febuxostat is a more potent inhibitor of XOR than allopurinol, as confirmed by that target UA levels have been achieved more freque...
Main Authors: | M. S. Petrova, М. M. Musiychuk, V. I. Mazurov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2018-09-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/844 |
Similar Items
-
GOUTY ARTHRITIS – MODERN VIEW OF THE PROBLEM
by: V. I. Mazurov, et al.
Published: (2017-11-01) -
FEBUXOSTAT FOR TREATMENT OF CHRONIC HYPERURICEMIA IN GOUT PATIENTS
by: M. S. Petrova, et al.
Published: (2017-11-01) -
Uric acid, gout and cardiovascular diseases: prospects for the use of urat-lowering medications
by: M. S. Eliseev, et al.
Published: (2019-08-01) -
Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy
by: Tao Han Lee, et al.
Published: (2021-09-01) -
Modern paradigm of treatment of hyperuricemia and gout in comorbid patients with the development of cardio-vascular pathology
by: V. I. Mazurov, et al.
Published: (2020-12-01)